Lieping Chen MD, PhD

United Technologies Corporation Professor in Cancer Research
Professor of Immunobiology, Dermatology and Medicine (Medical Oncology)
Director, Cancer Immunology Program at Yale Cancer Center
Yale University School of Medicine
New Haven, Connecticut

Dr. Lieping Chen is the world’s leading investigator in the characterization of cell surface co-stimulatory and co-inhibitory molecules that modulate immune responses. He is the first scientist to apply co-stimulation as a mean for cancer immunotherapy. His laboratory discovered immune suppressive function of the B7-H1 (PD-L1)/PD-1 pathway in cancer and first demonstrated using antibody to block this pathway to enhance tumor immunity for the therapy of cancer. His laboratory at Yale Cancer Center is actively engaged in the study of biochemical, structural and functional aspects of co-stimulatory and co-inhibitory molecules as well as development of new strategies using engineered proteins, monoclonal antibodies and gene transfer to manipulate co-stimulation against cancers.

Chen is professor of immunobiology, of dermatology, and of medicine (medical oncology) at Yale School of Medicine and director of the cancer immunology program at the Yale Cancer Center. He is also an adjunct professor at Johns Hopkins University School of Medicine in Baltimore, Maryland; Sun Yat-Sen University in Guangzhou, China; and Chinese Academy of Sciences in Beijing, China.

He earned his medical degree from Fujian Medical University, China; his M.S. from Beijing Union Medical College; and a Ph.D. from Drexel University. Chen served as a professor in the Department of Immunology at the Mayo Clinic in Rochester, Minnesota (2000-2004), and was a member of the faculty of Johns Hopkins University School of Medicine (2004-2010) before coming to Yale in 2010.

Chen has published more than 300 scientific papers, review articles, and book chapters, and has edited two books. He has delivered more than 200 speeches, seminars and lectures, and served on many committees and advisory boards for U.S. federal government and private organizations.

Among his numerous honors and awards are a Presidential Award from Bristol-Myers Squibb (1996), Milton Fromer Memorial Lectureship (1996), American Cancer Society Research Scholar (2000), and keynote speaker in the Congress of the Spanish Society of Immunology (2011).